2021
DOI: 10.1016/j.arbr.2020.08.013
|View full text |Cite
|
Sign up to set email alerts
|

The long road to biologic therapies for asthma in pediatric patients

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1

Citation Types

0
3
0

Year Published

2022
2022
2024
2024

Publication Types

Select...
3

Relationship

0
3

Authors

Journals

citations
Cited by 3 publications
(3 citation statements)
references
References 8 publications
0
3
0
Order By: Relevance
“…In addition to clinical treatment, there remains an unmet need for novel therapeutics to alleviate severe cases of acute asthma exacerbations. Little is known about the efficacy of biologic therapies in paediatric asthma, their optimum duration for treatment and potential long term side effects into adulthood 50 53 . Thus the Global Initiative for Asthma (GINA) recently published considerations for selecting biologic therapy for severe asthma in children younger than 18 years is helpful 54 .…”
Section: Discussionmentioning
confidence: 99%
“…In addition to clinical treatment, there remains an unmet need for novel therapeutics to alleviate severe cases of acute asthma exacerbations. Little is known about the efficacy of biologic therapies in paediatric asthma, their optimum duration for treatment and potential long term side effects into adulthood 50 53 . Thus the Global Initiative for Asthma (GINA) recently published considerations for selecting biologic therapy for severe asthma in children younger than 18 years is helpful 54 .…”
Section: Discussionmentioning
confidence: 99%
“…It would be interesting to advance research into the use of other monoclonal antibodies in children, as most are only available for adults. Indeed, a good control of asthma in children avoids the appearance of complications and improve the prognosis of these patients in adulthood [ 8 ].…”
Section: Discussionmentioning
confidence: 99%
“…Despite many advances in asthma treatment, including monoclonal antibodies targeting immunoglobulin E or interleukins pathways, many asthma pediatric patients remain uncontrolled, which leads to significant medical costs [ 8 ]. Uncontrolled pediatric asthma is associated with high exacerbation rates, impaired quality of life, and persistent bronchial obstruction [ 9 ].…”
Section: Introductionmentioning
confidence: 99%